|
1
|
Kubli SP, Berger T, Araujo DV and Mak L:
Beyond immune checkpoint blockade: Emerging immunological
strategies. Nat Rev Drug Discov. 20:899–819. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He X and Xu C: Immune checkpoint signaling
and cancer immunotherapy. Cell Res. 30:660–669. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang Q, Lei Y, Li X, Guo F and Liu M: A
Highlight of the mechanisms of immune checkpoint blocker
resistance. Front Cell Dev Biol. 8:5801402020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waldman AD and Lenardo J: A guide to
cancer immunotherapy: From T cell basic science to clinical
practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kruger S, Ilmer M, Kobold S, Cadilha B,
Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H,
et al: Advances in cancer immunotherapy 2019-latest trends. J Exp
Clin Cancer Res. 38:2682019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Darvin P, Toor S and Elkord V: Immune
checkpoint inhibitors: Recent progress and potential biomarkers.
Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Acevedo J, Kimbrough E and Lou Y: Next
generation of immune checkpoint inhibitors and beyond. J Hematol
Oncol. 14:452021. View Article : Google Scholar
|
|
9
|
Johnson D, Nebhan C, Moslehi J and Balko
J: Immune-checkpoint inhibitors: Long-term implications of
toxicity. Nat Rev Clin Oncol. 19:254–267. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Franzin R, Netti G, Spadaccino F, Porta C,
Gesualdo L, Stallone G, Castellano G and Ranieri E: The use of
immune checkpoint inhibitors in oncology and the occurrence of AKI:
Where do we stand? Front Immunol. 11:5742712020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wright J, Powers A and Johnson D:
Endocrine toxicities of immune checkpoint inhibitors. Nat Rev
Endocrinol. 17:389–399. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rao R and Dou Y: Hijacked in cancer: The
KMT2 (MLL) family of methyltransferases. Nat Rev Cancer.
15:334–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park K and Kim J: Transcriptional
regulation by the KMT2 histone H3K4 methyltransferases. Biochim
Biophys Acta Gene Regul Mech. 1863:1945452020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhai X and Brownell J: Biochemical
perspectives on targeting KMT2 methyltransferases in cancer. Trends
Pharmacol Sci. 42:688–699. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu J, Liu Z, Liang X, Wang L, Wu D, Mao W
and Shen D: A Pan-Cancer study of KMT2 family as therapeutic
targets in cancer. J Oncol. 2022:39822262022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen E, Shulha H, Weng Z and Akbarian S:
Regulation of histone H3K4 methylation in brain development and
disease. Philos Trans R Soc Lond B Biol Sci. 369:201305142014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bochyńska A, Firzlaff J and Lüscher B:
Modes of Interaction of KMT2 Histone H3 Lysine 4
Methyltransferase/COMPASS complexes with chromatin. Cells.
7:172018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rampias T, Karagiannis D, Avgeris M,
Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E,
Stravodimos K, et al: The lysine-specific methyltransferase
KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Rep.
20:e468212019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang A, Liu L, Ashby J, Wu D, Chen Y,
O'Neill SS, Huang S, Wang J, Wang G, Cheng D, et al: Recruitment of
KMT2C/MLL3 to DNA damage sites mediates DNA damage responses and
regulates PARP inhibitor sensitivity in cancer. Cancer Res.
81:3358–3373. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mendiratta G, Ke E, Aziz M, Liarakos D,
Tong M and Stites E: Cancer gene mutation frequencies for the U.S.
population. Nat Commun. 12:59612021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Na F, Pan X, Chen J, Chen X, Wang M, Chi
P, You L, Zhang L, Zhong A, Zhao L, et al: KMT2C deficiency
promotes small cell lung cancer metastasis through DNMT3A-mediated
epigenetic reprogramming. Nat Cancer. 3:753–767. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Zhang G, Chen B, Wang Y, Guo L,
Cao L, Ren C, Wen L and Liao N: Association between histone lysine
methyltransferase KMT2C mutation and clinicopathological factors in
breast cancer. Biomed Pharmacother. 116:1089972019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang P and Huang Y: Genomic alterations
in KMT2 family predict outcome of immune checkpoint therapy in
multiple cancers. J Hematol Oncol. 14:392021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang R, Wu H, Xu M and Xie X: KMT2A/C
mutations function as a potential predictive biomarker for
immunotherapy in solid tumors. Biomark Res. 8:712020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tu Z, Ouyang Q, Long X, Wu L, Li J, Zhu X
and Huang K: Protein Disulfide-Isomerase A3 is a robust prognostic
biomarker for cancers and predicts the immunotherapy response
effectively. Front Immunol. 13:8375122022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun D, Wang J, Han Y, Dong X, Ge J, Zheng
R, Shi X, Wang B, Li Z, Ren P, et al: TISCH: A comprehensive web
resource enabling interactive single-cell transcriptome
visualization of tumor microenvironment. Nucleic Acids Res.
49:D1420–D1430. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamb J: The connectivity map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin A, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin Y, Wang Z, He D, Zhu Y, Chen X and Cao
K: Identification of novel subtypes based on ssGSEA in
immune-related prognostic signature for tongue squamous cell
carcinoma. Cancer Med. 10:8693–8707. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Liu Q, Shen H, Liu Y, Wang Y, Wang
G and Du J: Identification and validation of a three
Pyroptosis-Related lncRNA signature for prognosis prediction in
lung adenocarcinoma. Front Genet. 13:8386242022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mariathasan S, Turley S, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiong D, Wang Y and You M: A gene
expression signature of TREM2hi macrophages and γδ T cells predicts
immunotherapy response. Nat Commun. 11:50842020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao J, Chen A, Gartrell R, Silverman A,
Aparicio A, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et
al: Immune and genomic correlates of response to anti-PD-1
immunotherapy in glioblastoma. Nat Med. 25:462–469. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim S, Cristescu R, Bass A, Kim M,
Odegaard J, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al:
Comprehensive molecular characterization of clinical responses to
PD-1 inhibition in metastatic gastric cancer. Nat Med.
24:1449–1458. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE and Brookland R: The Eighth Edition AJCC Cancer
Staging Manual: Continuing to build a bridge from a
population-based to a more ‘personalized’ approach to cancer
staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang WL, Jiang ZR, Hu C, Chen C, Hu ZQ,
Wang AL, Wang L, Liu J, Wang WC and Liu QS: Pharmacologically
inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta
Pharmacol Sin. 42:633–640. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan D, Kobayashi A, Jiang P, Ferrari de
Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, et al:
A major chromatin regulator determines resistance of tumor cells to
T cell-mediated killing. Science. 359:770–775. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gala K, Li Q, Sinha A, Razavi P, Dorso M,
Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh JJ, Berger M, et al:
KMT2C mediates the estrogen dependence of breast cancer through
regulation of ERα enhancer function. Oncogene. 37:4692–4710. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiong W, Deng H, Huang C, Zen C, Jian C,
Ye K, Zhong Z, Zhao X and Zhu L: MLL3 enhances the transcription of
PD-L1 and regulates anti-tumor immunity. Biochim Biophys Acta Mol
Basis Dis. 1865:454–463. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zheng J, Wang C, Gao C, Xiao Q, Huang C,
Wu M and Li LY: MLL3 suppresses tumorigenesis through regulating
TNS3 enhancer activity. Cell Death Dis. 12:3642021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sugie T: Immunotherapy for metastatic
breast cancer. Chin Clin Oncol. 7:282018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wrobel P and Ahmed S: Current status of
immunotherapy in metastatic colorectal cancer. Int J Colorectal
Dis. 34:13–25. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sharma P and Allison J: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vesely M, Zhang T and Chen L: Resistance
mechanisms to Anti-PD cancer immunotherapy. Annu Rev Immunol.
40:45–74. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schoenfeld A and Hellmann M: Acquired
resistance to immune checkpoint inhibitors. Cancer Cell.
37:443–455. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chan T, Yarchoan M, Jaffee E, Swanton C,
Quezada S, Stenzinger A and Peter S: Development of tumor mutation
burden as an immunotherapy biomarker: Utility for the oncology
clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Walk E, Yohe S, Beckman A, Schade A,
Zutter M, Pfeifer J and Berry AB; College of American Pathologists
Personalized Health Care Committee, : The cancer immunotherapy
biomarker testing landscape. Arch Pathol Lab Med. 144:706–724.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chang L, Chang M, Chang H and Chang F:
Microsatellite instability: A predictive biomarker for cancer
immunotherapy. Appl Immunohistochem Mol Morphol. 26:e15–e21. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen Y, Zhao B and Wang X: Tumor
infiltrating immune cells (TIICs) as a biomarker for prognosis
benefits in patients with osteosarcoma. BMC Cancer. 20:10222020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang B, Mason J, Jewett A, Liu M, Chen W,
Qian J, Ding Y, Ding S, Ni M, Zhang X and Man YG:
Tumor-infiltrating immune cells: Triggers for tumor capsule
disruption and tumor progression? Int J Med Sci. 10:475–497. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li T, Kang G, Wang T and Huang H: Tumor
angiogenesis and anti-angiogenic gene therapy for cancer. Oncol
Lett. 16:687–702. 2018.PubMed/NCBI
|
|
53
|
Liu ZL, Chen HH, Zheng LL, Sun LP and Shi
L: Angiogenic signaling pathways and anti-angiogenic therapy for
cancer. Signal Transduct Target Ther. 8:1982023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fang JW, Lu Y, Zheng JY, Jiang XC, Shen
HX, Shang X, Lu Y and Fu P: Exploring the crosstalk between
endothelial cells, immune cells, and immune checkpoints in the
tumor microenvironment: New insights and therapeutic implications.
Cell Death Dis. 14:5862023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhu L, Yu X, Wang L, Liu J, Qu Z, Zhang H,
Li L, Chen J and Zhou Q: Angiogenesis and immune checkpoint dual
blockade in combination with radiotherapy for treatment of solid
cancers: Opportunities and challenges. Oncogenesis. 10:472021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo FF and Cui JW: Anti-angiogenesis:
Opening a new window for immunotherapy. Life Sci. 258:1181632020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Iwahori K: Cytotoxic CD8+ lymphocytes in
the tumor microenvironment. Adv Exp Med Biol. 1224:53–62. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ugel S, Canè S, Sanctis F and Bronte V:
Monocytes in the tumor microenvironment. Annu Rev Pathol.
16:93–122. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wu S, Fu T, Jiang Y and Shao Z: Natural
killer cells in cancer biology and therapy. Mol Cancer. 19:1202020.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li X, Liu R, Su X, Pan Y, Han X, Shao C
and Shi Y: Harnessing tumor-associated macrophages as aids for
cancer immunotherapy. Mol Cancer. 18:1772020. View Article : Google Scholar
|
|
61
|
Liao Z, Tan Z, Zhu P and Tan N:
Cancer-associated fibroblasts in tumor microenvironment-Accomplices
in tumor malignancy. Cell Immunol. 343:1037292021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim J and Bae J: Tumor-Associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dirix V, Corbière V, Thomas CW, Selis E,
Allard S, Hites M, Aerts L, Giese T and Mascart F: Blood
tolerogenic monocytes and low proportions of dendritic cell
subpopulations are hallmarks of human tuberculosis. J Leukoc Biol.
103:945–954. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Safi M, Ahmed H, Al-Azab M, Xia YL, Shan
X, Al-Radhi M, Al-Danakh A, Shopit A and Liu J: PD-1/PDL-1
inhibitors and cardiotoxicity; molecular, etiological and
management outlines. J Adv Res. 29:45–54. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hashimoto M, Kamphorst AO, Im SJ, Kissick
HT, Pillai RN, Ramalingam SS, Araki K and Ahmed R: CD8 T cell
exhaustion in chronic infection and cancer: Opportunities for
interventions. Annu Rev Med. 69:301–318. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yang HS, Cui W and Wang LH: Epigenetic
synthetic lethality approaches in cancer therapy. Clin Epigenetics.
11:1362019. View Article : Google Scholar : PubMed/NCBI
|
